EnglishFifteen patients with advanced epithelial ovarian cancer were treated with 4-demethoxydaunorubicin (IMI-30) after platinum failure. A total of 33 courses of IMI-30 15 mg/m2, per os, daily for 3 consecutive days every 3 weeks were performed. Three patients experienced severe hematologic toxicity (WHO grade greater than or equal to 3), while gastroenteric toxicity was acceptable and no cardiotoxicity was observed. One minor response, 4 stabilization of disease and 7 progression were observed in 12 evaluable patients. In conclusion, IMI-30, at this scheduling, is inactive in our small series of heavily pretreated epithelial ovarian cancer patients.
4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study / M., Bruzzone; S., Chiara; A., Falcone; G., Graziani; Conte, Pierfranco; R., Rosso. - In: CHEMIOTERAPIA. - ISSN 0392-906X. - STAMPA. - 6(1987), pp. 137-139.
| Data di pubblicazione: | 1987 |
| Titolo: | 4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study. |
| Autore/i: | M., Bruzzone; S., Chiara; A., Falcone; G., Graziani; Conte, Pierfranco; R., Rosso |
| Autore/i UNIMORE: | |
| Rivista: | |
| Volume: | 6 |
| Pagina iniziale: | 137 |
| Pagina finale: | 139 |
| Codice identificativo ISI: | WOS:A1987H466900015 |
| Codice identificativo Scopus: | 2-s2.0-0023221410 |
| Codice identificativo Pubmed: | 3474080 |
| Citazione: | 4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study / M., Bruzzone; S., Chiara; A., Falcone; G., Graziani; Conte, Pierfranco; R., Rosso. - In: CHEMIOTERAPIA. - ISSN 0392-906X. - STAMPA. - 6(1987), pp. 137-139. |
| Tipologia | Articolo su rivista |
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
Copyright © 2021